ArticleInternal medicine (Tokyo, Japan)2026
Clinical Implications of Coexisting EWSR1 Rearrangements in Ewing Sarcoma: A Database Analysis and Representative Cases.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective Ewing sarcoma (ES) is a highly aggressive malignancy with a poor prognosis, particularly in metastatic disease. While localized disease treated with multimodal therapy achieves favorable survival rates, metastatic disease at presentation has a significantly poorer prognosis. The molecular hallmark of ES is the presence of EWSR1-ETS family fusion genes, with EWSR1-FLI1 being the most common gene. To investigate the impact of additional EWSR1 rearrangements on treatment outcomes in ES by analyzing a national cancer genomic database. Methods We conducted an exploratory retrospective analysis of the cancer genomic status and treatment response using the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database. Patients This study analyzed clinical genomic testing results from the C-CAT database, focusing on bone and soft tissue tumors identified as ES (n=90). Representative cases were selected to illustrate the clinical implications of the molecular findings. Results An analysis of the C-CAT database revealed that a subset of ES cases showed additional EWSR1 rearrangements beyond the primary fusion gene. Cases with coexisting rearrangements demonstrated higher rates of disease progression with first-line chemotherapy than those with isolated fusions. This finding was exemplified in our institutional experience, where ES with an isolated EWSR1-FLI1 fusion showed a good response to standard chemotherapy, whereas a case with an additional ETS1-EWSR1 rearrangement exhibited primary resistance to multiple lines of therapy. Conclusion These findings suggest that coexisting EWSR1 rearrangements may have important prognostic implications and warrant further investigation to optimize treatment strategies in resistant cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.